Antiviral Drug Development: The Road Less Taken

Fletcher CV . Pharmacologic considerations for antiviral drug development. Ann Pharmacother 1996; 30: 972–7.

Whitley RJ . The past as prelude to the future: history, status, and future of antiviral drugs. Ann Pharmacother 1996; 30: 967–71.

McKenzie R Fried MW Sallie R Conjeevaram H Di Bisceglie AM Park Y Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099–105.

Skowron G Bozzette SA Lim L Pettinelli CB Schaumburg HH Arezzo J Alternating and intermittent regimens of zidouvudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993; 118: 321–36.

Feinberg J Cooper D Hurwitz S . Therapy of HIV-1-associated opportunistic infections. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 19, 1995.

Fischl MA Richman DD Grieco MH Gottlieb MS Volberding PA Laskin OL The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185–91.

Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871–80.

Massari F Conant M Mellors J Steigbigel R Mildvan D Greenberg R A Phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 28-February 1, 1996.

Cameron B Heath-Chiozzi M Kravcik S Mills R Potthoff A Henry D . Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Presented at the 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 28–February 1, 1996.